The role of nucleoside reverse transcriptase inhibitors usage in the incidence of hyperlactatemia and lactic acidosis in HIV/AIDS patients

Biomedicine and Pharmacotherapy

Volumn 66, Issue 4, 2012, Pages 308-311

  Dragovic, Gordana ^a   Jevtovic, Djordje ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Didanosine; Hyperlactatemia; Lactic acidosis; Nucleoside analogs; Stavudine

Indexed keywords

ABACAVIR; DIDANOSINE; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG INDUCED DISEASE; FEMALE; FOLLOW UP; HUMAN; HYPERLACTATEMIA; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SERBIA; SEX DIFFERENCE;

ACIDOSIS, LACTIC; ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; CD4 LYMPHOCYTE COUNT; DIDANOSINE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; INCIDENCE; LACTIC ACID; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; SEX FACTORS; STAVUDINE;

EID: 84862491399     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2011.09.016     Document Type: Article

References (23)

1. Arenas-Pinto A., Grant A.D., Edwards S., Weller I.V.D. Lactic acidosis in HIV-1 infected patients: a systematic review of published cases. Sex Transm Infect 2003, 79:340-344.
2. Boubakker K., Flepp M., Sudre P., Furrer H., Haensel A., Hirschel B., et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis 2001, 33:1931-1937.
3. Fabian J., Venter W.D., Mkhabela L., Levin J.B., Baker L., Naicker S. Symptomatic hyperlactataemia in adults on antiretroviral therapy: a single-centre experience. S Afr Med J 2008, 98:795-800.
4. Clumeck N., Pozniak A., Raffi F. EACS Executive Committee. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med 2008, 9:65-71.
5. Hammer S.M., Saag M.S., Schechter M., Montaner J.S., Schooley R.T., Jacobsen D.M., et al. International AIDS Society-USA Panel. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006, 296:827-843.
6. Gazzard B. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2008, 9:795-848. for the BHIVA writing committee.
7. Hernández-Pérez E., Dawood H. Stavudine-induced hyperlactatemia/lactic acidosis at a tertiary communicable diseases clinic in South Africa. J Int Assoc Physicians AIDS Care 2010, 9:109-112.
8. Dragovic G.J., Smith C.J., Jevtovic D.J., Johnson M.A., Ranin J., Salemovic D., et al. Comparison of nucleoside reverse transcriptase inhibitor use as part of first-line therapy in a Serbian and a UK HIV clinic. HIV Clin Trials 2009, 10:306-313.
9. Arenas-Pinto A., Grant A., Bhaskaran K., Copas A., Carr A., Worm S.W., et al. Risk factors for fatality in HIV-infected patients with dideoxynucleoside-induced severe hyperlactataemia or lactic acidosis. Antivir Ther 2011, 16:219-226.
10. Stead D., Osler M., Boulle A., Rebe K., Meintjes G. Severe hyperlactataemia complicating stavudine first-line antiretroviral therapy in South Africa. Antivir Ther 2008, 13:937-943.
11. Manosuthi W., Prasithsirikul W., Chumpathat N., Suntisuklappon B., Athichathanabadi C., Chimsuntorn S., et al. Risk factors for mortality in symptomatic hyperlactatemia among HIV-infected patients receiving antiretroviral therapy in a resource-limited setting. Int J Infect Dis 2008, 12:582-586.
12. Tymchuk C.N., Currier J.S. The safety of antiretroviral drugs. Expert Opin Drug Saf 2008, 7:1-4.
13. Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy. AIDS 2007, 21:2455-2464. Lactic Acidosis International Study Group.
14. Fichtenbaum C.J. Metabolic abnormalities associated with HIV infection and antiretroviral therapy. Curr Infect Dis Rep 2009, 11:84-92.
15. McComsey G., Bai R.K., Maa J.F., Seekins D., Wong L.J. Extensive investigations of mitochondrial DNA genome in treated HIV-1-infected subjects: beyond mitochondrial DNA depletion. J Acquir Immune Defic Syndr 2005, 39:181-188.
16. Koczor C.A., Lewis W. Nucleoside reverse transcriptase inhibitor toxicity and mitochondrial DNA. Expert Opin Drug Metab Toxicol 2010, 6:1493-1504.
17. Lugassy D.M., Farmer B.M., Nelson L.S. Metabolic and hepatobiliary side effects of antiretroviral therapy (ART). Emerg Med Clin North Am 2010, 28:409-419.
18. Dragovic G., Jevtovic D.J. Nucleoside reverse transcriptase inhibitor usage and the incidence of peripheral neuropathy in HIV/AIDS patients. Antivir Chem Chemother 2003, 14:281-284.
19. Clark R. Sex differences in antiretroviral therapy-associated intolerance and adverse events. Drug Saf 2005, 28:1075-1083.
20. Currier J.S. Sex differences in antiretroviral therapy toxicity: lactic acidosis, stavudine, and women. Clin Infect Dis 2007, 45:261-262.
21. Kumarasamy N., Venkatesh K.K., Cecelia A.J., Devaleenol B., Saghayam S., Yepthomi T., et al. Gender-based differences in treatment and outcome among HIV patients in South India. J Womens Health 2008, 17:1471-1475.
22. Imhof A., Ledergerber B., Gunthard H.F., Haupts S., Weber R. Risk factors for and outcome of hyperlactatemia in HIV-1-infected persons: is there a need for routine lactate monitoring. Clin Infect Dis 2005, 41:721-728.
23. Osler M., Stead D., Rebe K., Meintjes G., Boulle A. Risk factors for and clinical characteristics of severe hyperlactataemia in patients receiving antiretroviral therapy: a case-control study. HIV Med 2010, 11:121-129.